Compare Dyne Therapeutics Inc. Common Stock (DYN) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs M&T Bank Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while M&T Bank Corporation trades at $215.86 (market cap $31.20B). The key difference: M&T Bank Corporation is far larger — about 10.9× Dyne Therapeutics Inc. Common Stock's market cap, and M&T Bank Corporation pays a 2.78% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and M&T Bank Corporation for 99 Days on average.
| DYN | MTB | |
|---|---|---|
Market Cap | $2.86B | $31.20B |
Volume | 3,341,579 | 795,459 |
Sector | Health | Financials |
52-Week High | $26.78 | $254.09 |
52-Week Low | $14.60 | $178.63 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $2.18B | $47.44B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
M&T Bank (MTB) trades at $217.93, down 0.89% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 11.54, net income margin of 30.85%, and three consecutive quarterly EPS beats. Recent news highlights loan growth, AI investments, and a new branch opening, while the company maintains a consistent dividend.
Outlook is cautiously optimistic given solid profitability and analyst consensus, but risks include negative net cash flow trends and elevated debt levels. The consensus price target of $256.62 suggests potential upside, contingent on continued earnings momentum and stable interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
